| 25228534 |
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
Okuno, Y,
Iafrate, AJ,
Friboulet, L,
Koike, S,
Shaw, AT,
Engelman, JA,
Khan, TM,
Lockerman, EL,
Takeuchi, K,
Taiji, M,
Fujita, N,
Gainor, JF,
Katayama, R
|
Clin Cancer Res |
2014 |
| 27432227 |
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Mino-Kenudson, M,
Friboulet, L,
Benes, CH,
Engelman, JA,
Yoda, S,
DiCecca, RH,
Digumarthy, S,
Le, LP,
Ritterhouse, LL,
Lennerz, J,
Sequist, LV,
Muniappan, A,
Parks, M,
Gainor, JF,
Schultz, K,
Dardaei, L,
Huynh, T,
Iafrate, AJ,
Keyes, C,
Dias-Santagata, D,
Heist, RS,
Shaw, AT,
Singh, M,
Logan, J,
Dagogo-Jack, I,
Leshchiner, I,
Channick, C,
Lee, D,
Chin, E,
Lockerman, E,
Getz, G,
Gadgeel, S,
Katayama, R
|
Cancer Discov |
2016 |
| 31668326 |
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib
Cordani, N,
Agustoni, F,
Cortinovis, D,
Arosio, G,
Mologni, L,
Sharma, GG,
Pagni, F,
Bidoli, P,
Bisson, WH,
Villa, M,
Gambacorti-Passerini, C,
Piazza, R
|
J Thorac Oncol |
2019 |
